GS
Therapeutic Areas
Amneal Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Brekiya (dihydroergotamine mesylate) | Acute Treatment of Migraine & Cluster Headache | Approved |
| CREXONT (Carbidopa/Levodopa) | Parkinson's Disease | Approved |
| Mesalamine DR | Gastroenterology (Ulcerative Colitis) | Approved |
| Everolimus | Oncology | Approved |
| Epinephrine (Adrenalin generic) | Emergency/Critical Care | Pending Approval |
| Prednisolone acetate | Ophthalmology | Approved |
| Risperidone ER | Psychiatry | Approved |
| Iohexol (Omnipaque generic) | Diagnostic Imaging | Pending Approval |
Leadership Team at Amneal Pharmaceuticals
CP
Chirag Patel
President and Co-Chief Executive Officer, Co-Founder
CP
Chintu Patel
Co-Chief Executive Officer, Co-Founder
TK
Tasos Konidaris
Executive Vice President, Chief Financial Officer
NS
Nikita Shah
Executive Vice President, Chief Human Resources Officer
JB
Jason B. Daly, Esq.
Executive Vice President, Chief Legal Officer & Corporate Secretary
AS
Andrew S. Boyer
Executive Vice President, Chief Commercial Officer – Generics & Biosciences
JR
Joe Renda
Senior Vice President, Chief Commercial Officer - Specialty
UK
Upendra Kumar Singh
President, India Business and Emerging Markets
SK
Srinivas Kone, PhD
Senior Vice President, Chief Scientific Officer – Generics
AD
Avinash Desai, MD
Senior Vice President, Chief Scientific Officer – Specialty